GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

The World Health Organization continues its investigation into the origins of COVID-19, with significant information still ...